Format

Send to

Choose Destination
Curr Opin Chem Biol. 2018 Jun;44:47-55. doi: 10.1016/j.cbpa.2018.05.004. Epub 2018 Jun 7.

Targeted protein degradation and the enzymology of degraders.

Author information

1
C4Therapeutics, Inc., 675 W. Kendall St., Cambridge, MA 02142, USA.
2
C4Therapeutics, Inc., 675 W. Kendall St., Cambridge, MA 02142, USA. Electronic address: aphillips@c4therapeutics.com.

Abstract

Targeted protein degradation is an emerging strategy for drug discovery that employs small molecules to catalyze the ubiquitination of target proteins, ultimately causing their degradation by the proteasome. Current degrader designs employ hetero-bivalent molecules to recruit E3 ubiquitin ligases such as VHL, Cereblon, and the IAPs to the target protein to be ubiquitinated. In this review, we describe some of the foundational studies underpinning the use of heterobivalent degraders for targeted protein degradation. We also present a framework for degraders as programmable essential activators of ubiquitin ligase enzymes, connecting their features as catalysts with established enzymology concepts.

PMID:
29885948
DOI:
10.1016/j.cbpa.2018.05.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center